Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fruquintinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIF5B | P33176 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fruquintinib SCHEMBL29366206 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| Fruquintinib SCHEMBL29516397 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| SCHEMBL12909830 | 0.93 | KDR (0.87) | KDRFLT1FLT4METAURKA | |
| SCHEMBL945594 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931698 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931690 | 0.90 | KDR (0.81) | KDRFLT1FLT4METAURKA | |
| SCHEMBL30753475 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753458 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753470 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL943909 | 0.88 | KDR (0.79) | KDRFLT1FLT4METAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600713-B2 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | HUTCHMED LIMITED (CN) | 2026-04-14 | — | — | US | claimed |
| US-20240279208-A1 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-08-22 | — | — | US | claimed |
| EP-3191475-B1 | CRYSTALLINE FORMS OF 6-((6, 7-DIMETHOXYQUINAZOLIN-4-YL)OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | HUTCHISON MEDIPHARMA LTD (CN) | 2020-07-29 | — | — | EP | claimed |
| US-20170283399-A1 | Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide | HUTCHMED LIMITED (CN) | 2017-10-05 | — | — | US | claimed |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD (CN) | 2026-05-12 | — | — | US | disclosed |
| WO-2026088214-A1 | Novel crystalline form of 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide and its process for the preparation | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2026-04-30 | — | — | WO | disclosed |
| US-12600713-B2 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | HUTCHMED LIMITED (CN) | 2026-04-14 | — | — | US | disclosed |
| US-12600713-B2 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | HUTCHMED LIMITED (CN) | 2026-04-14 | — | — | US | disclosed |
| US-12600713-B2 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | HUTCHMED LIMITED (CN) | 2026-04-14 | — | — | US | disclosed |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-7829574-B2 | compounds inhibit the activity of kinase insert domain receptor (KDR), such as 6-(6,7-bis(2-methoxyethoxy)quinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, used for treating cancer, age-related macula degeneration or chronic inflammatory diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-11-09 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137797-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137797-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600713-B2 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | ADH1A, CYP2C8, CYP4F8 | KDR 1183/4885FLT1 1728/4885FLT4 1069/4885 |
| US-20170283399-A1 | Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide | CYP2D6, CYP2A6, CYP2B6 | KDR 3085/4885FLT1 3944/4885FLT4 2543/4885 |
| US-20240279208-A1 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | CYP2D6, CYP2A6, CYP2B6 | KDR 3085/4885FLT1 3944/4885FLT4 2543/4885 |
| US-20090281130-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885FLT1 2/4885FLT4 1/4885 |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885FLT4 2/4885 |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | FLT1, KDR, FLT4 | KDR 2/4885FLT1 1/4885FLT4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.